IL211366A0 - Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers - Google Patents

Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Info

Publication number
IL211366A0
IL211366A0 IL211366A IL21136611A IL211366A0 IL 211366 A0 IL211366 A0 IL 211366A0 IL 211366 A IL211366 A IL 211366A IL 21136611 A IL21136611 A IL 21136611A IL 211366 A0 IL211366 A0 IL 211366A0
Authority
IL
Israel
Prior art keywords
cancers
malignant melanoma
cancer drugs
metastatic malignant
uses relating
Prior art date
Application number
IL211366A
Other languages
English (en)
Original Assignee
Kasina Laila Innova Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasina Laila Innova Pharmaceuticals Private Ltd filed Critical Kasina Laila Innova Pharmaceuticals Private Ltd
Publication of IL211366A0 publication Critical patent/IL211366A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40Thiophene-2-carboxylic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL211366A 2008-09-15 2011-02-23 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers IL211366A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2230CH2008 2008-09-15
PCT/IN2009/000504 WO2010029577A2 (en) 2008-09-15 2009-09-14 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Publications (1)

Publication Number Publication Date
IL211366A0 true IL211366A0 (en) 2011-04-28

Family

ID=41565903

Family Applications (1)

Application Number Title Priority Date Filing Date
IL211366A IL211366A0 (en) 2008-09-15 2011-02-23 Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Country Status (11)

Country Link
US (1) US8258119B2 (https=)
EP (1) EP2324006B1 (https=)
JP (1) JP2012502900A (https=)
KR (1) KR20110063537A (https=)
CN (1) CN102149703B (https=)
AU (1) AU2009290365B2 (https=)
BR (1) BRPI0913485A2 (https=)
CA (1) CA2736732A1 (https=)
IL (1) IL211366A0 (https=)
NZ (1) NZ591394A (https=)
WO (1) WO2010029577A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120006554A (ko) * 2009-04-27 2012-01-18 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 항암 약물, 및 악성 흑색종 및 다른 암에 대한 용도
NO2686520T3 (https=) 2011-06-06 2018-03-17
EP2717870B1 (en) * 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
US9593095B2 (en) 2013-06-14 2017-03-14 Duke University Methods for the treatment of bacterial infections
US10221198B2 (en) 2014-06-27 2019-03-05 Ecole Polytechnique Federale De Lausanne (Epfl) Preparation and medical use of triazenes
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
EP3297624B1 (en) 2015-05-18 2021-03-03 Syn-Nat Products Enterprise LLC A pharmaceutical co-crystal and use thereof
KR20180018800A (ko) 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴 계 공-결정의 약제학적 조성물 및 이의 용도
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CA2989001A1 (en) 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
EP3790863A1 (en) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
KR102648781B1 (ko) 2021-11-09 2024-03-19 국립공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020641B (de) 1955-10-15 1957-12-12 Basf Ag Verfahren zur Herstellung von Derivaten der 3-Oxythiophen-2-carbonsaeure
CA968347A (en) 1968-09-09 1975-05-27 John F. Gerster Substituted pyrazoles and process

Also Published As

Publication number Publication date
WO2010029577A2 (en) 2010-03-18
US8258119B2 (en) 2012-09-04
WO2010029577A3 (en) 2010-05-06
EP2324006A2 (en) 2011-05-25
KR20110063537A (ko) 2011-06-10
EP2324006B1 (en) 2014-08-13
CN102149703B (zh) 2014-09-10
CA2736732A1 (en) 2010-03-18
AU2009290365B2 (en) 2014-08-14
AU2009290365A1 (en) 2010-03-18
NZ591394A (en) 2013-03-28
CN102149703A (zh) 2011-08-10
JP2012502900A (ja) 2012-02-02
BRPI0913485A2 (pt) 2016-06-07
US20100068178A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
IL211366A0 (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
IL215789A0 (en) Anti-cancer drugs, and uses relating for malignant malignant melanoma and other cancers
EP2108630A4 (en) FRITTE DIAMOND
EP2168059A4 (en) INTEGRATED SHARING OF ELECTRONIC DOCUMENTS
DK2331118T5 (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
ZA201105791B (en) New adenosine receptor ligands and uses thereof
IL209854A0 (en) Supression of cancers
IL212905A0 (en) Individualized cancer dignosis
EP2140692A4 (en) BETTER ZONE DETERMINATION
IL190382A0 (en) Detecting prostate cancer
EP2520651A4 (en) SIRNA FOR INHIBITING THE C-MET EXPRESSION AND ANTICREPLAY COMPOSITION THEREWITH
ZA201004495B (en) Rotary machine scroll structure and rotary machine
EP2113496A4 (en) DIAMOND SINTER BODY
EP2268146A4 (en) ANTICANCER AGENTS BASED ON INDOLINE
AP2009004952A0 (en) Pharmaceutical carrier composition and pharmaceutical composition
IL214319A (en) Chemotherapeutic agent for cancer containing cholesterol derivative and anticancer agent
GB0714483D0 (en) Improvements in the chemotherapy of cancer
GB0809730D0 (en) Improvements in the chemotherapy of cancer
GB0818566D0 (en) Improvements in the chemotherapy of cancer
GB0722641D0 (en) Prevention of metastatic cancer
GB0718539D0 (en) Improvements in cancer chemotherapy
GB0822018D0 (en) Prevention of metastatic cancer
GB2440643B (en) Antitumor combinations comprising taxane derivatives
GB0808939D0 (en) Compacts comprising boron carbide and an ultrahard phase
GB0814307D0 (en) Compacts comprising boron carbide and an ultrahard phase